Thorne HealthTech, Inc. (THRN) has a consensus analyst rating of Buy, based on 6 analysts covering the stock. Of those, 4 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for THRN is $5.75, representing a -43.6% downside from the current price of $10.19. Price targets range from a low of $5.50 to a high of $6.00.
